thenextweb
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseases are treated. Candid Therapeutics is two years old. It does not have an approved drug. Its lead programme has been tested […]<br /> This story continues at The Next Web [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
What’s going on with Donut Lab?

In January, a Finnish-Estonian startup proclaimed it had developed a truly solid state battery, a holy grail for the technology industry. Donut Labs’ cell wasn’t just solid state, however. It clai [...]

Match Score: 160.96

qz
UCB is snapping up U.S. autoimmune biotech Candid Therapeutics for $2.2 billion

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune diseases [...]

Match Score: 135.42

Destination
Another big car company gives up on hydrogen

Stellantis, the automotive giant behind Chrysler, Citroen, Fiat, Jeep and Peugeot, is pulling out of hydrogen. The company said it’s killing its fuel cell development program in the face of “limi [...]

Match Score: 63.69

Destination
A revolutionary cancer treatment could transform autoimmune disease

Researchers are testing CAR T cell therapy as a way to reset the immune system. [...]

Match Score: 45.76

Destination
Netflix's Splinter Cell: Deathwatch animated series arrives on October 14

Ubisoft still isn’t giving us a new Splinter Cell game, but Sam Fisher fans are at least getting an animated TV adaptation very soon. At this week’s Anime NYC convention, Netflix revealed a new te [...]

Match Score: 45.49

qz
Eli Lilly is buying a biotech startup for nearly $3 billion to expand into autoimmune diseases

The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions [...]

Match Score: 41.21

thenextweb
Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by e [...]

Match Score: 40.15

thenextweb
Britain is spending £2bn to train its army inside an AI war simulation

Britain is spending £2bn to train its army inside a simulation. It has handed the job to an American defence giant, with a German one taking a slice. The UK has signed a £2bn ($2.7bn) contract to tr [...]

Match Score: 36.34

thenextweb
UPS is investing more than $2bn across international, healthcare and supply chain

UPS has told CNBC it is investing more than $2bn across its international, healthcare and supply chain businesses, spending that began in 2024 and runs to 2028. The same company cut about 48,000 roles [...]

Match Score: 36.34